Par Drugs and Chemicals Limited

As of March 31, 2026, Par Drugs and Chemicals Limited carries a market capitalization of 966.90M, placing it among publicly traded companies globally. Its enterprise value stands at 548.47M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, Par Drugs and Chemicals Limited has 12.30M shares outstanding.

As of March 31, 2026, Par Drugs and Chemicals Limited trades at a trailing price-to-earnings ratio of 7.39. The price-to-sales ratio is 0.93, and the price-to-book ratio stands at 0.86.

As of March 31, 2026, Par Drugs and Chemicals Limited trades at an EV/EBITDA multiple of 3.20 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.53 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 4.08 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 548.47M versus a market cap of 966.90M, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, Par Drugs and Chemicals Limited maintains a current ratio of 4.68, meaning it holds 4.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is - -, indicating a certain level of leverage, while an interest coverage ratio of 134.47 demonstrates strong ability to service its debt obligations.

Over the twelve months ended March 31, 2026, Par Drugs and Chemicals Limited posted a return on equity (ROE) of 12.43, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 9.25 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 10.55, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 12.52, useful for judging operating efficiency across full business cycles. The company generates approximately 8.62M in revenue per employee across its workforce of 120.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 7.56 indicates how many times Par Drugs and Chemicals Limited sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, Par Drugs and Chemicals Limited recorded 41.93M in income tax expense. That works out to an effective tax rate of 24.23, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 173.02M, leaving 131.09M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Par Drugs and Chemicals Limited's stock has gained approximately 3.72% over the past 52 weeks. The 50-day moving average sits at 121.21, while the 200-day moving average is 99.58.

Over the twelve months ended March 31, 2026, Par Drugs and Chemicals Limited generated 1.04B in revenue and converted that into 131.09M in net income, yielding earnings per share of 10.64. EBITDA reached 171.31M, while operating income came in at 134.28M.

As of March 31, 2026, Par Drugs and Chemicals Limited holds 418.43M in cash and equivalents against - - in total debt, resulting in a net debt position of -418.43M. Total book value stands at 1.12B, with working capital of 505.82M providing operational flexibility.

Over the twelve months ended March 31, 2026, Par Drugs and Chemicals Limited posted a gross margin of 58.17, reflecting its pricing power and cost economics. The operating margin of 12.95 and net profit margin of 12.65 provide insight into operational efficiency.

Par Drugs and Chemicals Limited's most recent stock split took place on April 27, 2021 with a 1:2 split ratio.

As of March 31, 2026, Par Drugs and Chemicals Limited has an Altman Z-Score of 5.95, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.